IV Diclofenac Dosing in Adults
The recommended intravenous dose of diclofenac sodium is 37.5 mg administered as a slow IV bolus over 5-30 seconds, which can be repeated after a minimum of 4-6 hours, with a maximum daily dose of 150 mg. 1
Standard Dosing
- Initial dose: 37.5 mg IV bolus (5-30 seconds)
- Repeat dosing: Can be given every 4-6 hours as needed
- Maximum daily dose: 150 mg per day
- Duration: Use the lowest effective dose for the shortest duration possible 1
Recent pharmacokinetic data demonstrates that a 75 mg/1 mL solution administered as a 5-second IV bolus achieves peak plasma concentrations (Cmax) approximately 2.7-fold higher than a 30-minute infusion, with earlier onset (0.05 vs 0.50 hours), suggesting superior analgesic effect 2.
Absolute Contraindications
Do NOT use IV diclofenac in patients with:
- Active peptic ulcer disease or gastrointestinal bleeding 3, 1
- Severe heart failure (NYHA Class III-IV) 3, 4, 5
- Severe chronic kidney disease (CrCl <30 mL/min or GFR <30 mL/min/1.73 m²) 3, 4
- Known hypersensitivity to NSAIDs or aspirin-induced asthma (aspirin triad) 1
- Perioperative pain in coronary artery bypass graft (CABG) surgery 6, 1
- Severe hepatic impairment 1
Dose Adjustments for Organ Dysfunction
Hepatic Impairment
- Mild hepatic impairment: No dose adjustment required based on pharmacokinetic studies 7
- Moderate to severe hepatic impairment: Avoid use entirely - hepatic metabolism accounts for nearly 100% of diclofenac elimination, and severe hepatotoxicity including liver necrosis and fulminant hepatitis has been reported 1
- Monitor transaminases within 4-8 weeks if treatment must be initiated 1
Renal Impairment
- Mild to moderate renal insufficiency (CrCl 30-90 mL/min): No routine dose adjustment necessary, as renal elimination is not a significant pathway for unchanged diclofenac 1, 7
- Severe CKD (CrCl <30 mL/min) or end-stage renal disease: Contraindicated - significantly higher AUC values and risk of acute kidney injury 4, 8
- Important caveat: While pharmacokinetics may not change dramatically, NSAIDs can precipitate acute-on-chronic renal failure in patients with compensated renal insufficiency 1
Critical Safety Considerations
Cardiovascular Risks
Diclofenac carries the highest cardiovascular risk among NSAIDs 6. Meta-analysis shows:
- 63% increased risk of vascular events vs placebo (RR 1.63,95% CI 1.12-2.37) 6
- 54% increased risk of recurrent MI (RR 1.54,95% CI 1.23-1.93) 6
- 140% increased risk of mortality (RR 2.40,95% CI 2.09-2.80) 6
Both high-dose (≥150 mg/day) and low-dose (<150 mg/day) diclofenac carry similar cardiovascular risks 9, contradicting the assumption that lower doses are safer.
Drug Interactions - ACE Inhibitors and Heart Failure
Acute administration of diclofenac causes profound renal dysfunction in heart failure patients on ACE inhibitors 5:
- 40% reduction in GFR compared to placebo
- Significant decreases in urine flow, sodium and potassium excretion
- Can precipitate acute decompensation of heart failure
This combination should be avoided 4, 5.
Gastrointestinal Protection
For patients who must receive diclofenac despite GI risk factors:
- Co-prescribe a proton pump inhibitor (PPI) for gastroprotection 3, 10, 11
- Risk factors include: age >60 years, history of peptic ulcer disease, concomitant corticosteroids or anticoagulants, alcohol use 12, 1
Monitoring Requirements
Before initiating treatment:
- Measure blood pressure
- Check baseline renal function (BUN, creatinine)
- Screen for unrecognized CKD in high-risk patients
- Obtain baseline liver function tests (ALT, AST, alkaline phosphatase) 1, 11
During treatment:
- Monitor blood pressure and renal function closely 11
- Repeat transaminases within 4-8 weeks, then periodically 1
- Discontinue immediately if transaminases exceed 3× upper limit of normal or if signs of hepatotoxicity develop 1
Practical Algorithm
- Screen for absolute contraindications (active GI ulcer, severe heart failure, severe CKD, NSAID hypersensitivity)
- If contraindications present: Use alternative analgesics (opioids are safer in these contexts) 3, 4
- If no contraindications but high cardiovascular risk: Consider naproxen or celecoxib instead 11
- If diclofenac selected: Use 37.5 mg IV bolus, repeat q4-6h PRN, max 150 mg/day
- Add PPI if any GI risk factors present
- Monitor BP and renal function within 1 week, then periodically
- Use shortest duration possible - limit to acute pain management only
Common pitfall: Assuming low-dose diclofenac is cardiovascularly safe - recent evidence shows equivalent risk at all doses 9.